HIF1A and anemia (phenotype): Moreover, thorough Food and Drug Administration review has allayed these concerns, and allowed a number prolyl-hydroxlase inhibitor (HIF-1 boosting) drugs to enter human clinical trials for chronic administration in anemia patients, including FG-4592 (FibroGen, Astellas and AstraZeneca, ClinicalTrials.gov #NCT01887600, Phase III), AKB-6548 (Akebia Therapeutics, #NCT01235936, Phase II), and GSK1278863 (Glaxo-SmithKline, #NCT01977573, Phase II) [82].